Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Dividends payables Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Non-Current Assets Non-Current Debt Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

TherapeuticsMD (TXMD) Short term Debt (2021 - 2022)

TherapeuticsMD filings provide 3 years of Short term Debt readings, the most recent being $93.6 million for Q3 2022.

On a quarterly basis, Short term Debt rose 524.01% to $93.6 million in Q3 2022 year-over-year; TTM through Sep 2022 was $93.6 million, a 524.01% increase, with the full-year FY2021 number at $188.3 million, changed N/A from a year prior.
Short term Debt hit $93.6 million in Q3 2022 for TherapeuticsMD, up from $90.8 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $202.9 million in Q1 2022 to a low of $5.0 million in Q1 2021.